Zelira Therapeutics Limited (ZLDAF)
USD 0.3
(-10.08%)
USD 0.3
(-10.08%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 5.06 Million AUD | 1738.55% |
| 2023 | 291.69 Thousand AUD | 112.99% |
| 2022 | -2.24 Million AUD | 49.2% |
| 2021 | -4.42 Million AUD | -315.14% |
| 2020 | -1.06 Million AUD | 65.35% |
| 2019 | -3.07 Million AUD | 45.95% |
| 2018 | -5.68 Million AUD | 27.73% |
| 2017 | -7.86 Million AUD | -933.19% |
| 2016 | 944.3 Thousand AUD | 390.92% |
| 2015 | -324.59 Thousand AUD | 45.68% |
| 2014 | -597.53 Thousand AUD | 38.35% |
| 2013 | -969.3 Thousand AUD | 24.19% |
| 2012 | -1.27 Million AUD | -62.26% |
| 2011 | -787.96 Thousand AUD | -129.49% |
| 2010 | -343.35 Thousand AUD | 82.02% |
| 2009 | -1.9 Million AUD | -74.58% |
| 2008 | -1.09 Million AUD | -135.41% |
| 2007 | 3.08 Million AUD | 196.22% |
| 2006 | 1.04 Million AUD | 171.42% |
| 2005 | -1.45 Million AUD | 32.16% |
| 2004 | -2.15 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.66 Million AUD | 9.73% |
| 2024 FY | 3.24 Million AUD | 1013.98% |
| 2024 Q4 | 5.06 Million AUD | 5.83% |
| 2024 Q3 | 5.06 Million AUD | 205.23% |
| 2024 Q1 | 1.51 Million AUD | 167.38% |
| 2023 Q4 | -2.24 Million AUD | -1605.35% |
| 2023 FY | 291.69 Thousand AUD | 112.99% |
| 2023 Q1 | 227.11 Thousand AUD | 110.11% |
| 2023 Q2 | 360.4 Thousand AUD | 58.69% |
| 2023 Q3 | 149.16 Thousand AUD | -58.61% |
| 2022 Q1 | -7.19 Million AUD | -62.78% |
| 2022 Q4 | -2.24 Million AUD | 4.94% |
| 2022 FY | -2.24 Million AUD | 49.2% |
| 2022 Q2 | -7.07 Million AUD | 1.63% |
| 2022 Q3 | -2.36 Million AUD | 66.62% |
| 2021 Q3 | -4.51 Million AUD | 44.44% |
| 2021 Q2 | -8.11 Million AUD | 0.56% |
| 2021 Q1 | -8.16 Million AUD | -666.7% |
| 2021 FY | -4.42 Million AUD | -315.14% |
| 2021 Q4 | -4.42 Million AUD | 2.01% |
| 2020 Q4 | -1.06 Million AUD | 5.41% |
| 2020 Q3 | -1.12 Million AUD | 3.78% |
| 2020 FY | -1.06 Million AUD | 65.35% |
| 2020 Q1 | -1.19 Million AUD | 61.18% |
| 2020 Q2 | -1.16 Million AUD | 1.93% |
| 2019 FY | -3.07 Million AUD | 45.95% |
| 2019 Q1 | -4.41 Million AUD | 22.43% |
| 2019 Q2 | -4.41 Million AUD | 0.0% |
| 2019 Q3 | -3.07 Million AUD | 30.32% |
| 2019 Q4 | -3.07 Million AUD | 0.0% |
| 2018 FY | -5.68 Million AUD | 27.73% |
| 2018 Q2 | -6.61 Million AUD | 0.0% |
| 2018 Q3 | -5.68 Million AUD | 14.01% |
| 2018 Q4 | -5.68 Million AUD | 0.0% |
| 2018 Q1 | -6.61 Million AUD | 15.96% |
| 2017 Q1 | -3.59 Million AUD | -6346.7% |
| 2017 FY | -7.86 Million AUD | -933.19% |
| 2017 Q4 | -7.86 Million AUD | 0.0% |
| 2017 Q3 | -7.86 Million AUD | -119.14% |
| 2017 Q2 | -3.59 Million AUD | 0.0% |
| 2016 Q4 | -55.69 Thousand AUD | 0.0% |
| 2016 FY | 944.3 Thousand AUD | 390.92% |
| 2015 Q4 | -324.59 Thousand AUD | 0.0% |
| 2015 FY | -324.59 Thousand AUD | 45.68% |
| 2014 FY | -597.53 Thousand AUD | 38.35% |
| 2014 Q4 | -597.53 Thousand AUD | 0.0% |
| 2013 Q4 | -969.3 Thousand AUD | 0.0% |
| 2013 FY | -969.3 Thousand AUD | 24.19% |
| 2012 FY | -1.27 Million AUD | -62.26% |
| 2012 Q4 | -1.27 Million AUD | 0.0% |
| 2011 FY | -787.96 Thousand AUD | -129.49% |
| 2011 Q4 | -787.96 Thousand AUD | 0.0% |
| 2010 FY | -343.35 Thousand AUD | 82.02% |
| 2010 Q4 | -343.35 Thousand AUD | 0.0% |
| 2009 FY | -1.9 Million AUD | -74.58% |
| 2009 Q4 | -1.9 Million AUD | 0.0% |
| 2008 FY | -1.09 Million AUD | -135.41% |
| 2008 Q4 | -1.09 Million AUD | 0.0% |
| 2007 FY | 3.08 Million AUD | 196.22% |
| 2007 Q4 | 3.08 Million AUD | 0.0% |
| 2006 FY | 1.04 Million AUD | 171.42% |
| 2006 Q4 | 1.04 Million AUD | 0.0% |
| 2005 FY | -1.45 Million AUD | 32.16% |
| 2005 Q4 | -1.45 Million AUD | 0.0% |
| 2004 Q4 | -2.15 Million AUD | 0.0% |
| 2004 FY | -2.15 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 852.847% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -317.446% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -402.853% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 88.159% |
| GB Sciences, Inc. | 1.74 Million USD | -190.007% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 157.323% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 54773.555% |
| Skye Bioscience, Inc. | -5.72 Million USD | 188.568% |
| Zenith Capital Corp. | 10.06 Thousand USD | -50251.063% |
| Agentix Corp. | 37.63 Thousand USD | -13365.842% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 10.287% |
| Biomind Labs Inc. | 711.4 Thousand USD | -612.302% |
| ContraFect Corporation | -6.02 Million USD | 184.091% |
| CSL Limited | 10.52 Billion USD | 99.952% |
| CytoDyn Inc. | 20.26 Million USD | 74.991% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1308.727% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -714.207% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 88.333% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 24930.121% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -446.528% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -697.795% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 180.376% |
| SQZ Biotechnologies Company | -36.23 Million USD | 113.983% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -489.059% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 67.853% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -125.995% |
| Mesoblast Limited | 55.85 Million USD | 90.928% |
| Marizyme, Inc. | 18.56 Million USD | 72.711% |
| Genus plc | 190.6 Million USD | 97.341% |
| Pharming Group N.V. | 109.8 Million USD | 95.385% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -645.196% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -338.567% |
| IMV Inc. | 7.67 Million USD | 33.938% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 7.898% |
| MultiCell Technologies, Inc. | 90.04 USD | -5627766.504% |
| ONE Bio Corp. | 9.04 Million USD | 43.946% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 60.858% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 83.415% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -153.444% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 60.432% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -3524.597% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -25406.272% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2857.161% |
| Enzolytics Inc. | 981.65 Thousand USD | -416.202% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.25% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 110.779% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 28.336% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.477% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -23.052% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1161.004% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -112.375% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2980.276% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 27763.124% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -126.642% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -3663.643% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 790.393% |
| Helix BioMedix, Inc. | -2.57 Million USD | 297.17% |
| EV Biologics, Inc. | 1.36 Million USD | -270.427% |
| Q BioMed Inc. | 4.06 Million USD | -24.811% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 75.008% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 91.631% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | -13.312% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -130.126% |
| HST Global, Inc. | 96.79 Thousand USD | -5135.225% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 386919.16% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -2357.281% |
| Halberd Corporation | 144.72 Thousand USD | -3401.448% |
| Resverlogix Corp. | 6.45 Million USD | 21.449% |
| Cell Source, Inc. | 9.23 Million USD | 45.111% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -87.082% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | 185.84% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -2428.205% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | -132.61% |
| Kadimastem Ltd | -253.1 Thousand USD | 2102.09% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -3626.28% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -2417.878% |
| LadRx Corporation | -2.03 Million USD | 348.829% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -697.795% |
| Affymax, Inc. | -5.59 Million USD | 190.537% |
| Itoco Inc. | 228.3 Thousand USD | -2119.544% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -2.226% |
| Mobile Lads Corp. | 484.23 Thousand USD | -946.468% |
| International Stem Cell Corporation | 2.59 Million USD | -95.65% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | -166.854% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 783304.173% |
| Qrons Inc. | 351.42 Thousand USD | -1341.93% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 34.242% |
| SYBLEU INC | 473.71 Thousand USD | -969.703% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 2130.018% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1561.42% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -13.693% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -8019.031% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -132.35% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -47.564% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 40.754% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -555.874% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 505.386% |
| Neutra Corp. | 52.18 Thousand USD | -9609.949% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 303.589% |
| PureTech Health plc | -167.19 Million USD | 103.031% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 2169.075% |
| IXICO plc | -4.44 Million USD | 214.011% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 61.666% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 90.762% |
| CSL Limited | 10.52 Billion USD | 99.952% |
| Cellectis S.A. | -43.81 Million USD | 111.564% |